What Avia Pharma does

Avia Pharma AB is a Northern European pharmaceutical distribution and brand company founded in 2016, headquartered in Stockholm, Sweden, with operations across the Nordics (Sweden, Norway, Denmark, Finland, Iceland) and Germany (Munich and Greven offices). The company distributes a portfolio of more than 30 OTC pharmaceuticals, prescription drugs, medical devices, and food supplements organised around five therapeutic areas: women's health, urology, dermatology, allergy, and general OTC. Its product mix combines own-developed and acquired brands (e.g., Nix, Duroferon, Allergika, Allpresan, Ceraderm, MagneCit, Otocur) with in-licensed products from international partners including Perrigo, Theramex, Endoceutics, Nemysis, and Pohl-Boskamp. The portfolio spans well-established consumer healthcare franchises (Vitamin D drops, iron supplements, magnesium, zinc, scabies and lice treatments) and prescription pharmaceuticals (Spedra, Adenuric, Binosto, Intrarosa, Nyvigan) targeting specific therapeutic needs such as erectile dysfunction, gout, osteoporosis, vaginal atrophy, and vulvovaginal candidiasis. A notable recent product is Tolfer, an iron supplement based on patented IHAT (Iron Hydroxide Adipate Tartrate) technology licensed from Nemysis and launched in Sweden and Finland in late 2025.

The company's go-to-market relies on pharmacy distribution networks across Northern Europe, with both own sales capabilities and partnerships with regional distributors. Revenue is generated through one-time product sales (OTC and prescription) rather than subscription or licensing-out models. Avia Pharma has executed an active buy-and-build strategy, completing seven acquisitions since inception including Pharmaprim (2020), Decem Pharma (2022), Allergika Pharma GmbH (2022), Unimedic Vitamin D oil (2022), ACO Vitamin D water (2023), Neubourg Skin Care GmbH (2024), and Allderma AB (2026), each adding branded products, geographic reach, and revenue. The company is co-founded by CEO Jacob Calmvik and Jostein Lønberg, with a leadership team drawn from pharmacy, pharma, and consulting backgrounds (BCG, GlaxoSmithKline, Apotek Hjärtat, Baxter). In January 2024, Nordic healthcare investor Impilo AB became a new owner and partner to the founders, providing growth capital and adding Per Edelmann as board chairperson. Reported group revenue exceeded EUR 55 million in 2024, up from c. EUR 40 million in 2022.

Name

Avia Pharma

Legal name

Avia Pharma AB

Website

https://aviapharma.se

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Avia Pharma is a Northern European pharmaceutical company distributing more than 30 OTC, prescription, and medical device products across the Nordics and Germany through pharmacy channels, organised around women's health, urology, dermatology, allergy, and general OTC therapeutic areas.

Ownership category

akta.pro rank

Product category

OTC and prescription pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

OTC & Consumer Health Distributors (HLAIAJAC)

akta.pro secondary industries

Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Eye, Ear & Nasal Care (HLAIADAF), Dermatology & Acne Prescribing + Pharmacy Delivery Platforms (HLALAIAK), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• OTC pharmaceuticals
• Prescription drugs
• Women's health products
• Dermatology products
• Pharmacy distribution

Headquarters

HQ city

Danderyd

HQ country

Sweden

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sales of own-brand and licensed pharmaceutical products through pharmacy channels across Northern Europe. The company sells both OTC products and prescription drugs through pharmacies in Nordic countries and Germany.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Avia Pharma is a Northern European pharmaceutical distribution and marketing company that sells OTC products, prescription drugs, medical devices, and food supplements across five therapeutic areas (women's health, urology, dermatology, allergy, and general OTC) to pharmacies in Sweden, Norway, Denmark, Finland, Iceland, and Germany. The company combines proprietary brand products (e.g., Duroferon, Nix, Ceraderm, MagneCit) with licensed and in-licensed pharmaceuticals from international partners, sold primarily through pharmacy channels with 30+ products in its portfolio.

Product overview

Avia Pharma is a Northern European pharmaceutical company founded in 2016, operating across Sweden, Norway, Denmark, Finland, Iceland, and Germany with offices in Stockholm, Helsinki, Munich, and Greven. The company focuses on five therapy areas: women's health, urology, dermatology, allergy, and general OTC. The portfolio comprises over 30 products combining proprietary brands with licensed pharmaceuticals from international partners. Women's health products include Intrarosa (vaginal atrophy), Nyvigan (vulvovaginal candidiasis), and Binosto (osteoporosis). Urology offerings include Adenuric (gout) and Spedra (erectile dysfunction). Dermatology spans prescription and OTC products including Ceraderm skincare line, Nix (lice/scabies), Rosazol (rosacea), Xyliderm (atopic skin), Kelo-Cote (scars), and Allergika allergy products. General OTC includes iron supplements (Tolfer with IHAT technology, Duroferon), vitamin D products for children, MagneCit magnesium supplement, Oralmedic (mouth ulcers), Otocur (ear care), and Thermal Care medical devices. The company has grown through acquisitions including Pharmaprim (2020), Decem Pharma (2022), Allergika Pharma GmbH (2022), Neubourg Skin Care (2024), and Allderma (2026), as well as licensing partnerships with Theramex, Nemysis, and Perrigo.

Differentiator

Problem solved

Functional benefit

Brands

• Ceraderm: Skincare range manufactured in Finland for dry, irritated, and damaged skin, widely used in Finnish hospitals
• MagneCit
• Otocur
• Buminifom/Minifom
• Duroferon/Ferro Duretter
• Spedra
• Adenuric
• NIX
• D-Vitamin Vatten Avia
• Allergika
• Vectavir
• Rosazol
• Kelo-Cote
• Ceraderm Betaglucan
• Ceraderm Intime
• Curemid
• Cremarol
• D-vitamin Olja Pharmaprim
• D-vitamin Olja ACO
• Tolfer
• Oralmedic
• Dentosal
• Thermal Care
• Zincit
• Intrarosa
• Nyvigan
• Binosto

Products and services

• Duroferon Slow-release iron(II)sulphate tablets for treating iron deficiency and iron deficiency anemia; also used prophylactically in pregnancy and blood donation.
• Tolfer Iron supplement containing IHAT (Iron Hydroxide Adipate Tartrate) technology providing 30mg elemental iron per capsule, designed for high absorption and gastrointestinal tolerance.
• Nix Cream containing 5% permethrin for killing scabies mites and crabs; 1% shampoo formulation for treating head lice.
• Spedra Avanafil tablet, a second-generation PDE5 inhibitor for treating erectile dysfunction in adult men; approved in EU in 2014 with higher selectivity than older PDE5 inhibitors.
• Adenuric Febuxostat tablet for treatment of chronic hyperuricaemia where urate deposition has occurred including tophus and/or gouty arthritis.
• Intrarosa Prasterone (DHEA) vaginal pessary for treating vulvar and vaginal atrophy in postmenopausal women; an inactive precursor steroid converted locally to estrogens and androgens.
• Binosto Buffered effervescent alendronate tablet for treating postmenopausal osteoporosis and reducing risk of vertebral and hip fractures.
• Nyvigan Nystatin combination treatment (pessaries plus cream) for treating vulvovaginal candidiasis; shows good effect with no development of resistance in Candida strains.
• Ceraderm Skincare range manufactured in Finland for dry, irritated, and damaged skin; forms a breathable barrier on skin surface, strengthening the protective layer.
• Allergika Dermatology product line for atopic/allergic skin, atopic dermatitis, dry skin, and sun sensitivity including eyelid/facial creams, protective hand creams, sunscreens, and lip repair products.
• Allergika Encasings Encasings for pillows, blankets, and mattresses as well as travel encasings to prevent allergic reactions to house dust mites.
• MagneCit Magnesium citrate supplement with vitamin B6 for reducing tiredness and fatigue and maintaining normal nervous and muscular system function.
• Otocur Oil-based ear spray developed in Finland for preventing recurrent earwax impaction, treating earwax plugs, preventing ear canal infections, and treating dry/itchy ear canals.
• Oralmedic Clinically proven treatment for mouth ulcers containing a sulfonated phenolic compound that removes damaged tissue and seals the ulcer surface for pain relief and healing.
• Kelo-Cote Advanced formula silicone gel for improving scar appearance; clinically proven to soften, flatten, and reduce discoloration of raised scars.
• Rosazol Metronidazole 1% cream for treating redness and skin changes associated with rosacea.
• Xyliderm
• Vectavir Penciclovir-based cold sore cream for treating herpes labialis caused by Herpes simplex virus by stopping viral reproduction.
• Minifom/Buminifom Simeticone-based soft capsules for relieving colic and flatulence in infants by reducing surface tension to prevent foaming in the gastrointestinal tract.
• D-Vitamin Vatten Avia
• D-vitamin Olja Pharmaprim
• Dentosal
• Thermal Care
• Zincit
• Curemid
• Cremarol
• Theramex Women's Health Portfolio (HRT and contraceptives) Distribution and representation of Theramex women's health portfolio in the Nordics, including Hormone Replacement Therapy (HRT) pharmaceuticals and contraceptives.
• Pohl-Boskamp Nordic Portfolio

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Pohl-BoskampcoreChannel Partner/ Reseller/ Distributor · 13 March 2026Strategic partnership and distribution agreement where Avia Pharma acts as Pohl-Boskamp's official distributor in the Nordic region. Products include GeloRevoice throat lozenges (Denmark, Norway, Sweden), Nitrolingual nitroglycerin spray (Denmark, Norway, Sweden), and Gepan instill bladder treatment (Denmark, Finland, Norway, Sweden).
• Allderma ABcoreStrategic or Co-development Partner · 2 March 2026Acquisition of Allderma AB, a Swedish consumer healthcare company. Adds approximately EUR 14 million in annual sales with brands including Daxxin, Terclara, Hårkontroll, and Lactiplus.
• Nemysis LimitedcoreChannel Partner/ Reseller/ Distributor · 2 December 2025Exclusive agreement to introduce Tolfer, a next-generation iron supplement containing IHAT (Iron Hydroxide Adipate Tartrate), to the Nordic market. Tolfer provides a well-tolerated and highly bioavailable solution for iron deficiency prevention and treatment.
• TheramexcoreChannel Partner/ Reseller/ Distributor · 1 January 2025Official representation partnership in the Nordics for Theramex, a global specialty pharmaceutical company specializing in women's health products. Includes pharmaceuticals within Hormone Replacement Therapy (HRT) and contraceptives.
• Neubourg Skin Care GmbHcoreStrategic or Co-development Partner · 2 February 2024Acquisition of Neubourg Skin Care GmbH, a leading German dermatology company specializing in skin, foot and nail care. Generates annual revenues of c. EUR 15m with brands including Allpresan, Podoexpert, and Onyfix.
• Allergika Pharma GmbHcoreStrategic or Co-development Partner · 29 July 2022Acquisition of Allergika Pharma GmbH, a German pharmaceutical company focused on the allergy market. Allergika sells both dermatology products and encasings under its own brands, with a turnover of close to 15 million EUR.
• Decem PharmacoreStrategic or Co-development Partner · 1 April 2022Acquisition of Decem Pharma, a Finnish pharmaceutical company with strong brands including Magnecit and Otocur. This was Avia Pharma's first acquisition outside of Sweden and part of its strategy to build a northern European pharmaceutical company.
• Pharmaprim ABcoreStrategic or Co-development Partner · 3 August 2020Acquisition of Pharmaprim AB, a Swedish pharmaceutical company with products in urology, rheumatology and endocrinology. Had sales of approximately 15 million SEK.
• Viiral ASminorChannel Partner/ Reseller/ Distributor · 7 June 2019License agreement to launch Viiral, a nasal spray for prevention of viral infections with neuraminic acid as active ingredient.
• Se-cureminorChannel Partner/ Reseller/ Distributor · 5 January 2019License agreement to launch Femarelle, a non-hormonal option for women during menopausal transition.
• PerrigocoreChannel Partner/ Reseller/ Distributor · 1 July 2018Expanded cooperation including Vectavir, Vectatone, Oralmedic, and Predictor products. Perrigo is a leading consumer self-care company.
• EndoceuticscoreChannel Partner/ Reseller/ Distributor · 5 February 2018Long-term license agreement for Nordic commercial rights to Intrarosa (prasterone) for the treatment of vaginal atrophy in postmenopausal women.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Karo Healthcare: Swedish-headquartered specialist consumer-health and OTC platform with a similar roll-up playbook across Northern Europe. Closely comparable to Avia in target therapeutic categories (women's health, dermatology, OTC) and in operating model (own brands plus licensed products sold through pharmacy channels).
• Orion Corporation: Finnish specialty pharma company with a broad portfolio spanning prescription, OTC, and consumer health products across the Nordics and broader Europe. Comparable in Nordic geographic footprint, multi-therapeutic-area structure, and pharmacy-led distribution.
• Dermapharm Holding: German specialty pharma group focused on dermatology, allergy, and OTC products. Highly comparable to Avia's Allergika/Neubourg dermatology franchise and shares the German OTC wholesale-and-brand-build model.
• Almirall: European dermatology-focused specialty pharma. Comparable to Avia in dermatology category focus and European pharmacy-channel commercialization model.
• Recordati: European specialty pharma group with strong presence in urology, women's health, and rare diseases. Comparable to Avia in therapeutic-area mix and European specialty-pharmacy distribution approach.
• ACO Hud: Nordic OTC and self-care company with strong heritage brands in vitamin D, emollients, and personal care. Directly comparable as a Nordic-headquartered OTC peer whose former brands (ACO Karbamid, ACO Glycerol, ACO Vitamin D) Avia has acquired.

Broad incumbents

• Stada Arzneimittel: Large European generics and consumer-health company with a broad OTC portfolio across multiple therapeutic areas. Operates at greater scale than Avia but competes head-to-head in pharmacy-channel OTC across the same DACH and Nordic geographies.
• Perrigo Company: Global consumer self-care leader and an existing Avia partner (cooperation on Vectavir, Vectatone, Oralmedic, Predictor). Comparable as a broad incumbent whose products Avia distributes and whose divestments (ACO Karbamid, ACO Glycerol) Avia has acquired.
• Bayer Consumer Health: OTC division of a global pharma major with leading brands across dermatology, allergy, and general OTC. Competes with Avia in German pharmacy channels and sets the benchmark for category scale in the regions where Avia operates.

Regional players

• Gedeon Richter: Central/Eastern European-headquartered pharma with growing women's health and OTC franchises. Comparable to Avia in therapeutic-area emphasis (especially women's health) but primarily serving different geographies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avia Pharma